¹⁸FDG beim primären Staging von Lungentumoren

Zusammenfassung

Die Diagnostik von Primärtumoren der Lunge erfordert ein exaktes Staging nach der TNM-Klassifikation. Im Gegensatz zu den bereits etablierten bildgebenden Verfahren beschreibt ¹⁸FDG die funktionellen metabolischen Vorgänge im Tumorgewebe als Folge einer gesteigerten Glykolyse. Das Ziel der Studie war die Anwendung von ¹⁸FDG beim primären Staging von Lungentumoren. 44 Patienten wurden auf einer Gammakamera mit einem 511 keV Kollimator untersucht. Die ¹⁸FDG Akkumulation pulmonaler Tumoren und deren Metastasen erzielt bei den mit anderen bildgebenden Verfahren beschriebenen Herden (107) eine Sensitivität von 85%, bei den histologisch verifizierten Herden (50) von 89%, bei den Primärtumoren (35) von 100% sowie bei den Metastasen (63) von 76%. Als Alternative zu ¹⁸FDG PET Untersuchungen ist ein primäres Staging von Lungentumoren auch mit einer ECT-geeigneten Gammakamera und einem 511 keV Kollimator möglich.

Summary

The diagnosis of primary lung tumors requires a precise staging according to the TNM classification. In contrast to established imaging methods ¹⁸FDG describes the functional metabolic processes in the tumor tissue due to increased glycolysis. This paper describes the use of ¹⁸FDG in the primary staging of lung tumors and metastases. 44 patients were studied with a gamma camera and a 511 keV collimator. In comparison to pulmonary tumors and metastases detected by other imaging methods (107) the accumulation of ¹⁸FDG has a sensitivity of 85%, in lesions verified by histology (50) of 89%, in primary tumors (35) of 100% and in metastases (63) of 76%. As an alternative to FDG PET studies, primary staging of lung tumors is possible with a gamma camera, suitable for ECT and fitted with a 511 keV collimator.

Schlüsselwörter

Lungentumor - ¹⁸FDG - SPECT

Keywords

Lung tumors - ¹⁸FDG - SPECT

^* Kliniken für Nuklearmedizin der Stadt Wuppertal, FRG

• Literatur

• 1 Bustos R, Sobino F. Stimulation of glycolysis as an activation signal in rat peritoneal macrophages. Biochem J 1992; 282: 299-303.
• 2 Callagher BM, Fowler JS, Gutterson NI. et al. Metabolic trapping as a principle of radiopharmaceutical design: Some factors responsible for the biodistribution of ¹⁸F-2-deoxy-2-fluoro-d-glucose. J Nucl Med 1978; 19: 1154-61.
• 3 Caskey CI, Zerhouni EA. The solitary pulmonary nodule. Semin Roentgenol 1990; 25: 85-95.
• 4 Cones DJ, Tarver RD, Gray WC. et al. Treatment of pneumothoraces utilizing small caliber chest tube. Chest 1988; 94: 55-7.
• 5 Di Chiro G, De La Paz RL, Brooks RA. et al. Glucose utilization of cerebral gliomas measured by F-18 fluorodeoxyglucose and positron emission tomography. Neurology 1982; 32: 1323-9.
• 6 Fischmann AJ, Alpert NM. FDG PET in oncology: There’s more to it than looking at pictures. J Nucl Med 1993; 34: 6-11.
• 7 Gupta NC, Frank AR, Dewan NA. et al. Solitary pulmonary nodules: Detection of malignancy with PET with 2-F-18 fluoro-2-deoxy-d-glucose. Radiology 1992; 184: 441-4.
• 8 Haberkorn U, Strauss LG, Dimitrakopoulou A. et al. PET studies of fluorodeoxyglucose metabolism with recurrent colorectal cancer receiving radiotherapy. J Nucl Med 1991; 32: 1485-90.
• 9 Höh CK, Hawkins RA, Glaspy JA. et al. Cancer detection with whole body PET using 2-F-18 fluoro-2-deoxy-d-glucose. J Comput Assist Tomogr 1993; 17: 582-9.
• 10 Horton RW, Meldrum BS, Bachelard HS. Enzymatic and cerebral metabolic effects of 2-deoxy-d-glucose. J Neurochem 1973; 21: 506-20.
• 11 Khouri NF, Meziane MA, Zerhouni EA. et al. The solitary pulmonary nodule: Assessment, diagnosis and management. Chest 1987; 91: 128-33.
• 12 Knoop MV, Bischoff HG, Ostertag H. et al. Clinical applications of FDG-PET for staging of bronchogenic carcinoma. J Nucl Med 1993; 31: 21P.
• 13 Knoop MV, Bischoff HG. Beurteilung von pulmonalen Herden mit der Positronenemissionstomographie. Radiologe 1994; 34: 58891.
• 14 Knuuti J, Nuntila P, Ruotsalainen U. et al. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography. J Nucl Med 1992; 33: 1255-62.
• 15 König R, Steinbächer M, van Kaick G. et al. Was leistet die Computertomographie für die Stadieneinteilung des Bronchialkarzinoms?. Röntgenpraxis 1985; 38: 189-93.
• 16 Kubota K, Matzuzawa T, Fuyiwara T. et al. Differential diagnosis of lung tumors with positron emission tomography: A prospective study. J Nucl Med 1990; 31: 1927-32.
• 17 Kubota R, Kubota K, Yamada S. et al. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissue and cancer cells by the dynamics of fluorine-18-fluoro-deoxyglucose uptake. J Nucl Med 1994; 35: 104-12.
• 18 Langen KJ, Braun U, Rota Kops E. et al. The influence of the plasma glucose level on F-18 deoxyglucose uptake in human pulmonary neoplasms. 2nd European Workshop on FDG in oncology. Heidelberg 1991
• 19 Layer G, van Kaick G. Staging des nichtkleinzelligen Bronchialkarzinoms mit CT und MRT. Radiologe 1990; 30: 155-63.
• 20 Lindholm P, Minn H, Leskinen-Kallio S. et al. Influence of the blood glucose concentration on FDG uptake in cancer – a PET study. J Nucl Med 1993; 34: 1-6.
• 21 Lowe VI, Hoffmann JM, Patz EF. et al. Differentiation of benign and malignant pulmonary opacities with PET-FDG. J Nucl Med 1993; 34: 21P.
• 22 Nolop KB, Rhodes CG, Brudin LH. et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987; 60: 2682-9.
• 23 Patz EF, Lowe VI, Hoffmann JM. et al. Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993; 183: 487-90.
• 24 Piatt JF, Glaser M, Orringer MB. et al. Radiologic evaluation of subcarinal lymph nodes: A comparative study. Am J Radiol 1988; 38: 279-82.
• 25 Rege SD, Hoh CK, Glapsy JA. et al. Imaging of pulmonary mass lesions by whole-body positron emission tomography and fluorodeoxyglucose. Cancer 1993; 72: 82-90.
• 26 Rhodes CG, Valind SO, Brudin LH. et al. Modulation of pulmonary glucose utilization by dietary state in man. Clin Sci 1985; 68: 21.
• 27 Schaner EG, Chang AE, Doppmann DM. et al. Comparison of computed and conventional whole lung tomography in detecting pulmonary nodules: A prospective radiologie-pathologie study. Am J Radiol 1978; 131: 51-4.
• 28 Schwickert HC, Thelen M, Schweden F. et al. Staging des nicht kleinzelligen Bronchialkarzinoms mit CT und MRT. Radiologe 1990; 30: 155-63.
• 29 Seely JM, Mayo JR, Miller RR. et al. T₍ lung cancer: Prevalence of mediastinal nodal metastases and diagnostic accuracy of CT. Radiology 1993; 186: 129-32.
• 30 Swensen SJ, Jett JR, Payne WS. et al. An integrated approach to evaluation of the solitary pulmonary nodule. Mayo Clin Proc 1990; 65: 173-86.
• 31 Wahl RL, Hutchins GD, Buchsbaum DJ. et al. ^l8F-2-deoxy-2-fluoro-d-glucose uptake into human tumor xenografts. Cancer 1991; 67: 1544-50.
• 32 Warburg O. On the origin of cancer cells. Science 1956; 123: 309-14.
• 33 Yonekura Y, Benua RS, Brill AB. et al. Increased accumulation of 2-deoxy-2-F-18 fluoro-d-glucose in liver metastases from colon carcinoma. J Nucl Med 1982; 23: 1133-7.